

**Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form**



This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	Name
ID Number	Specialty
D.O.B. <input type="checkbox"/> Male <input type="checkbox"/> Female	Address
Diagnosis	City /State/Zip
Drug Name	Phone: Fax:
Dose and Quantity	NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.

STEP 1: DISEASE STATE INFORMATION

Required Demographic Information:

Patient Weight: _____ *kg*
Patient Height: _____ *ft* _____ *inches*

Will the provider be administering the medication to the FEP member within the health plan's geographic service area?
 Yes No *If No, a prior authorization is not required through this process.*

Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.

Is this member's FEP coverage primary or secondary coverage?
 If primary, continue with question set.
 If secondary, **an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.**

Site of Care:

- A. At what location will the member be receiving the requested medication?
 Physician's office, home infusion, non-hospital affiliated ambulatory infusion center.
 Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting. _____
 Other. Please specify. _____

Criteria Questions:

- What drug is being prescribed?
 Aralast NP Glassia ProLactin-C Zema ira
- What is the patient's diagnosis?
 Emphysema
 Other diagnosis (*please specify*): _____
- Is the patient currently a smoker? Yes No

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.

4. Has the patient been on this medication continuously for the last **2 months**, excluding samples?

Please select answer below:

NO – this is **INITIATION** of therapy, please answer the following questions:

a. Is there documentation of alpha₁ antitrypsin (AAT) deficiency? Yes* No

**If YES*, was the deficiency determined by radial immunodiffusion, nephelometry or serum AAT level?

Immunodiffusion: What is the patient's level? _____ mg/dl

Nephelometry: What is the patient's level? _____ mg/dl

Serum AAT level: What is the patient's level? _____ um/L (micromolar per liter)

Other (please specify): _____

b. Does the patient have documentation of progressive emphysema with moderate airflow obstruction evidenced by forced expiratory volume (FEV₁) of 30-65% of predicted value? Yes No*

**If NO*, does the patient have documentation of progressive emphysema and has had a rapid decline in lung function as measured by change in FEV₁ greater than 120 ml/year? Yes No

YES – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

a. Has the alpha₁ antitrypsin (AAT) level been elevated to above the protective threshold? Yes No*

**If NO*, has there been a reduction in the rate of deterioration of lung function as shown by a reduction in forced expiratory volume (FEV₁) rate of decline? Yes No

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required)

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
Step 2: Checklist	<input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Provide chart notes	<input type="checkbox"/> Attach test results
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.